첨단의료복합단지 제5차 종합계획 수립 연구 ◈ 목차 제1장 추진 개요 ·································································································· 1 제1절 추진 배경 및 수립 경과 ······················································································· 1 1. 추진 배경 ······························································································································· 1 2. 정책 추진 여건 ····················································································································· 2 3. 수립 근거 및 경과 ··············································································································· 5 제2절 추진체계 ·················································································································· 8 1. 전략기획위원회 구성·운영 ··································································································· 8 2. 전략기획위원회 추진 경과 ································································································ 10 제2장 대내외 환경분석 11 제1절 메가트렌드 분석 ·································································································· 11 1. 정치적 요인 ························································································································· 11 2. 경제적 요인 ························································································································· 13 3. 사회적 요인 ························································································································· 15 4. 기술적 요인 ························································································································· 17 제2절 국내외 바이오헬스 산업 환경분석 ··································································· 21 1. 정책 환경분석 ····················································································································· 21 2. 시장 환경분석 ····················································································································· 50 3. 기술 환경분석 ····················································································································· 75 제3절 국내외 바이오클러스터 현황분석 ··································································· 108 1. 해외 바이오클러스터 현황분석 ······················································································ 108 2. 국내 바이오클러스터 현황분석 ······················································································ 115 제4절 종합 분석 ············································································································ 132 1. 외부 환경요인 분석 ········································································································· 132 2. 정책 추진여건 분석 ········································································································· 134 제3장 제1~4차 종합계획 현황 및 성과분석 137 제1절 정책변화 및 경과 ······························································································ 137 1. 제1~4차 종합계획 정책변화 ··························································································· 137 2. 제1~4차 종합계획 추진 경과 ························································································· 138 제2절 그간의 성과 ········································································································ 140 1. 제1~3차 종합계획 주요 내용 및 성과 ········································································· 140 2. 제4차 종합계획 주요 내용 및 성과 ············································································· 143 제3절 성과 및 한계 ······································································································ 149 1. 제1~4차 종합계획 성과 ·································································································· 149 2. 제1~4차 종합계획 한계 및 보완할 점 ········································································· 150 제4장 첨단의료복합단지 현황 및 성과분석 153 제1절 첨단의료복합단지 현황 ···················································································· 153 1. 첨단의료복합단지 일반현황 ··························································································· 153 2. 국가 예산 투입 현황 ······································································································· 157 3. 주요시설 ···························································································································· 160 4. 입주기관·기업 ···················································································································· 161 제2절 첨단의료산업진흥재단 현황 ············································································· 164 1. 대구경북첨단의료산업진흥재단 ······················································································ 164 2. 오송첨단의료산업진흥재단 ····························································································· 192 제3절 첨복재단 심층 비교분석 ·················································································· 221 1. R&D 예산 및 인력 현황 ································································································ 221 2. 기술서비스 현황 및 성과 ······························································································· 225 3. 양 재단 비교분석 결과 ··································································································· 230 제4절 첨단의료복합단지의 한계 ················································································ 231 1. 단지 및 재단 현황 분석 ································································································· 231 2. 단지 및 재단 한계 분석 ································································································· 235 제5장 전문가 위원회 운영 239 제1절 전략기획위원회 ·································································································· 239 1. 전략기획위원회 개요 ······································································································· 239 2. 전략기획위원회 주요의견 ······························································································· 240 제2절 분과위원회 ·········································································································· 242 1. 평가분석 분과 ··················································································································· 242 2. 바이오클러스터 분과 ······································································································· 246 3. 과제기획 분과 ··················································································································· 250 4. 3개 분과 연석회의 ··········································································································· 256 제6장 제5차 종합계획 추진방향 및 비전체계도 259 제1절 제5차 종합계획 수립방향 설정 ······································································ 259 1. SWOT 분석 ····················································································································· 259 2. 전략방향 도출 ··················································································································· 261 제2절 제5차 종합계획 비전체계도 ············································································ 263 1. 기본 개요 ·························································································································· 263 2. 비전체계도 ························································································································· 264 3. 추진전략 ···························································································································· 265 4. 비전-목표-추진전략 간 연계성 ······················································································ 267 5. 제1~4차 종합계획과의 차별점 및 연계방안 ······························································· 268 제7장 전략별 중점 추진과제 271 제1절 산업생태계 강화를 위한 혁신 지원 ······························································· 271 1. 수요 맞춤형 기술서비스 제공 ······················································································· 271 2. 사업화 및 창업·성장 지원 ······························································································ 273 3. 글로벌 인허가·규제 지원체계 구축 ·············································································· 275 제2절 공공적 역할 중심의 기반 R&D 강화 ···························································· 277 1. 핵심인프라 보강 R&D 지원 ··························································································· 277 2. 보건안보·공공 기술서비스 특화 R&D 지원 ································································ 281 3. 현장수요 기반 국산 의료기기 실증 및 글로벌 진출 R&D ······································ 284 제3절 첨복단지 중심의 연계와 협력 ········································································· 286 1. 단지 內-단지 間 연계‧협력 강화 ·················································································· 286 2. 他 클러스터 및 지역 생태계와 협력 강화 ·································································· 288 3. 글로벌 네트워크 조성 및 해외 진출 지원 ·································································· 291 제4절 인프라 고도화 및 전문인력 양성 ··································································· 293 1. 노후장비 개선 등 인프라 고도화 ·················································································· 293 2. 산업 수요 기반 전문인력 양성 ····················································································· 296 제5절 첨단의료복합단지 운영기반 안정화 ······························································· 298 1. 거버넌스 개편 등 제도 개선 ························································································· 298 2. 정주여건 개선 ··················································································································· 302 참고문헌 ·································································································································· 305 ◈본문 제1장 추진 개요 제1절 추진 배경 및 수립 경과 1. 추진 배경 □ 바이오헬스 산업 육성을 위한 첨단의료복합단지의 역할 증대 ❍ 바이오헬스 산업은 국가 경제성장에 미치는 효과가 큰 분야로, 투자·첨단기술·전문인력이 필요하여 주체 간 집적 및 협력 필요 ❍ 첨복단지는 정부 조성 클러스터로, 산업 성장세 및 기업·연구기관 등의 지원 수요 증가에 발맞춰 국내 바이오헬스 산업 선도 역할 필요 □ 국가 거점 클러스터로서 성장을 위한 변화가 필요한 시점 ❍ 첨단의료복합단지 조성계획(’10~’38년)의 반환점에 진입함에 따라, 15년간의역할·성과·한계 분석을 바탕으로 첨복단지 재정비 필요 ❍ 지역 클러스터에서 벗어나 국가 거점 클러스터로 도약을 위한 첨단의료복합단지 중장기 발전 방향 설정 필요 □ 첨복단지의 정체성 확립과 경쟁력 강화 위한 종합계획 수립 필요 ❍ 他 클러스터*와의 차별성이 부족하고, 단지 내 주체 간 연계·협력이 미흡하여 첨복단지의 정체성 확립과 경쟁력 강화에 대한 요구 발생 ＊ 정부·지자체·민간 등에서 첨단의료단지법, 연구개발특구법, 지자체 조례 등 다양한법령을 근거로 전국에 20여개의 바이오클러스터를 조성·운영 중 ❍ 글로벌 기술패권 경쟁 심화*에 따라, 국가 거점 클러스터로서 수행해야 하는 공공적 역할에 대한 고려 필요 ＊ 美(생물보안법), EU(바이오기술 및 바이오제조 이니셔티브), 中 (바이오굴기) 등 ❍ 재단 인프라 구축, 수익 사업 고도화 등 재단 중심의 종합계획에서 클러스터로서의 정체성을 바탕으로 한 단지 중심의 종합계획 필요 ...................(계속) ☞ 자세한 내용은내용바로가기또는첨부파일을 이용하시기 바랍니다.